Product Information
LAMIVUDINE-ZIDOVUDINE TABLET is a generic product labeled by Aurobindo Pharma Limited, priced at $0.7351 per EA under NDC 65862003660. Its NADAC has been published 250 times since Nov 10, 2021.
FDA first approved this application on May 5, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150; 300 mg/1; mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
65862003660
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
LAMIVUDINE; ZIDOVUDINEApproval Type
Generic (ANDA)
FDA Application
ANDA077558FDA Approved
5/5/2017
TE Code
AB
On Market Since
5/5/2017
Pharmacological Classes
Price Statistics
The NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has been published 250 times since Nov 10, 2021, and over the history we have for it it has declined 24.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7351 per EA |
|---|---|
| All-time high | $0.9767 (Dec 15, 2021) |
| All-time low | $0.5570 (Jan 21, 2026) |
| 52-week high | $0.7351 |
| 52-week low | $0.5570 |
| Median price | $0.6464 |
| Average price | $0.6895 |
| Largest weekly change | -35.6% (Dec 22, 2021) |
| Weeks tracked | 250 |
| Tracking since | Nov 10, 2021 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of LAMIVUDINE-ZIDOVUDINE TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LAMIVUDINE-ZIDOVUDINE TABLET, manufactured by Aurobindo Pharma Limited, is $0.7351 per EA (NDC 65862003660), effective Aug 19, 2026.
How has the price of LAMIVUDINE-ZIDOVUDINE TABLET changed over time?
Over the history we have for it, the NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has declined 24.7%. It has been tracked across 250 weekly CMS publications since Nov 10, 2021.
What are the highest and lowest recorded NADAC prices for LAMIVUDINE-ZIDOVUDINE TABLET?
Since Nov 10, 2021, the NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has ranged from a low of $0.5570 (Jan 21, 2026) to a high of $0.9767 (Dec 15, 2021), with a median of $0.6464 per EA.
Are there cheaper alternatives to LAMIVUDINE-ZIDOVUDINE TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LAMIVUDINE-ZIDOVUDINE TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures LAMIVUDINE-ZIDOVUDINE TABLET?
LAMIVUDINE-ZIDOVUDINE TABLET (NDC 65862003660) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.